All News
Drug Safety Differences with New Novel Therapies in RA
Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular differences for specific infection or other adverse event risks.
Read Article
Do you use TNFi in pregnant patients? @RheumNow #RWCS23 @RWCSmtg
Dr. Rachel Tate uptoTate ( View Tweet)
Low dose prednisolone in RA. GLORIA shows toxicity can be a real issue. @RWCSmtg @RheumNow #RWCS23 https://t.co/KstyKdjWn2
Dr. Rachel Tate uptoTate ( View Tweet)
2022 EULAR recs for RA treatment @RheumNow @RWCSmtg #RWCS23 https://t.co/nWCcFJyIhz
Dr. Rachel Tate uptoTate ( View Tweet)
Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live!
Among our 24 speakers, Dr. Sergio and Monica Schwartzman will cover All in the Family Rheumatology. Dr. Philip Conaghan will cover Insights into the Future of OA and more.
https://t.co/gAKQYxhTMY https://t.co/zMOGfhRrg2
Links:
Dr. John Cush RheumNow ( View Tweet)
Know Your Numbers! Have a chance to tune in to last week's podcast?
https://t.co/A6bYIahvBF https://t.co/ZAgZ3FvL0H
Links:
Dr. John Cush RheumNow ( View Tweet)
Lg vessel US study compared 44 LV-GCA vs 42high-risk atherosclerosis pt.Intima-media thickness (IMT) was signif. higher w/ GCA. IMT ≥ 1 mmseen in 31/44 axillary, 30/44 subclavian in GCA; but only in 2/42 axillary & 3//42 subclavian in atherosclerosis grp.https://t.co/DGMOfflcVR https://t.co/QVBbdrcd3I
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 64 gout pts having orthopedic surgery - perioperative flares more likely with Incr SUA, DM, tophi and diuretics. In 12 mos following surgery, recurrent gout more if ^SUA (45% vs 11%) & those w/ topic ((RR = 4.8; P = 0.029) https://t.co/iMDSWnb5Dv https://t.co/ZwUKBkZbSL
Links:
Dr. John Cush RheumNow ( View Tweet)
NOVESA trial ziritaxestat (an autotaxin inhibitor) in 33 early diffuse systemic sclerosis pts. After 24 wks, ziritaxestat showed signif reduction in mRSS (–8.9 vs. –6.0 PBO; P=0.04). It was well tolerated & showed biologic effect w/ reduced LPA C18:2 https://t.co/GKC2TKOQhE https://t.co/AUaminOyiH
Links:
Dr. John Cush RheumNow ( View Tweet)
Large-scale genome-wide association study of R A (276,020 samples in 5 ancestral grps) identified 124 loci (P < 5 × 10−8), 34 being novel. Candidate genes showed essential roles for TNIP2, TNFRSF11A, WISP1 in RA. https://t.co/jk1ePlen5l https://t.co/aSIZYJ9oky
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of HBV reactivation in HBsAg−/HBcAb+ RA ( 26 studies 2252 pts) Rx w/
b/tsDMARDs. Pooled HBV reactivation = 2%. Reactivation higher w/ RTX (esp if HBsAb−)
RTX 9% (p .03)
ABA 6%
JAKi 1%
IL‐6i 0%
TNFi 0%
Safe to use TNFi, JAKi, IL6 mAbs
https://t.co/YCIISZTigX https://t.co/RmzAObr6w1
Links:
Dr. John Cush RheumNow ( View Tweet)
Subanalysis of DISCOVER-1 RCT w/ IL-23 inhibitor guselkumab, showed similar response in TNFi-naive (n 118) & TNFi-experienced (263) Rx w/ guselkumab Q4W (76% & 68%) or Q8W (61% & 58%), yet skin responses (PASI90) were better in TNFi-naive Rx PsA pts.
https://t.co/tsKuLZw7dQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! Will we see you there?
https://t.co/hQOwBQtOny https://t.co/wwNF0gjpEj
Links:
Dr. John Cush RheumNow ( View Tweet)
Without DMARDS, Shoulder Arthroplasty Increasing in Rheumatoid Arthritis
The need for total shoulder arthroplasty (TSA) in rheumatoid arthritis (RA) patients appears to depend on the use of DMARDs, according to Seminars in Arthroplasty.
https://t.co/iGAQaa7Ppc https://t.co/AbteC427wI
Links:
Dr. John Cush RheumNow ( View Tweet)
Does Methotrexate Increase Skin Cancer Risk?
A report from the British Journal of Cancer has also shown an increased risk of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) with MTX use; and more so with higher doses.
https://t.co/tNNpFC6LiN https://t.co/x8Fuus2r8O
Links:
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib - Effective in Systemic Lupus Erythematosus
A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE.
https://t.co/0g2VM6TJt6 https://t.co/f6wylPc5ep
Links:
Dr. John Cush RheumNow ( View Tweet)
Recent Cochrane review of Vit D, Calcium and OP shows no evidence to support the isolated or combined use of calcium & vit D in premenopausal women to improve BMD (hip or spine) or results in the prevention of fractures (vertebral and non‐vertebral). https://t.co/ZbXuPAJcGv https://t.co/pai4gmMKoI
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort study of Taiwan Health Insurance Database looked at risk of #SLE in pts w/ Hashimoto’s thyroiditis (HT). Compared 15K HTvs 31K controls. SLE was incr in HT pts (IRR 3.58; p < 0.01). Several sensitivity analyses aHR 4.35 to 5.11 https://t.co/QaWEN4Chw9 https://t.co/bD8zrCJEXY
Links:
Dr. John Cush RheumNow ( View Tweet)
NLRP12 is a negative regulator of innate immune activation and type I interferon production. SLE PBMCs have low levels NLRP12 (inverse correl w/ IFNa & Hi Dz activity. NLRP12 knockouts or deficiency Incr autoAbs, inflammation & renal damage https://t.co/VICAqKmK9r https://t.co/MxqcNzh6BQ
Links:
Dr. John Cush RheumNow ( View Tweet)
New 5 Peptide Autoantibody Panel Complements RA Diagnosis
Antibodies to peptides not currently used for rheumatoid arthritis (RA) diagnosis helped identify patients with untreated early disease that conventional biomarkers missed, researchers said.
https://t.co/lOZvXBp7c1 https://t.co/6JVpeOyGYu
Links:
Dr. John Cush RheumNow ( View Tweet)